Cascade Investment Advisors Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 38.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,827 shares of the biopharmaceutical company’s stock after purchasing an additional 781 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.0% of Cascade Investment Advisors Inc.’s investment portfolio, making the stock its 28th largest holding. Cascade Investment Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,785,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Magnus Financial Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Magnus Financial Group LLC now owns 985 shares of the biopharmaceutical company’s stock worth $622,000 after acquiring an additional 37 shares during the last quarter. Rhumbline Advisers raised its stake in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Rhumbline Advisers now owns 161,999 shares of the biopharmaceutical company’s stock valued at $102,306,000 after purchasing an additional 732 shares in the last quarter. Good Life Advisors LLC raised its stake in Regeneron Pharmaceuticals by 2.8% during the fourth quarter. Good Life Advisors LLC now owns 3,146 shares of the biopharmaceutical company’s stock valued at $1,987,000 after purchasing an additional 87 shares in the last quarter. Roundview Capital LLC raised its stake in shares of Regeneron Pharmaceuticals by 10.5% in the fourth quarter. Roundview Capital LLC now owns 368 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 35 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Regeneron Pharmaceuticals by 11.9% in the fourth quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock valued at $2,899,642,000 after acquiring an additional 489,084 shares during the period. Institutional investors and hedge funds own 83.83% of the company’s stock.
In other news, CFO Robert E. Landry sold 83 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $686.00, for a total transaction of $56,938.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert E. Landry sold 325 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, April 8th. The shares were sold at an average price of $737.79, for a total transaction of $239,781.75. Following the completion of the sale, the chief financial officer now directly owns 28,744 shares in the company, valued at approximately $21,207,035.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,559 shares of company stock valued at $30,297,368. Insiders own 11.84% of the company’s stock.
REGN traded up $11.56 during trading on Friday, reaching $645.52. 604,540 shares of the company’s stock were exchanged, compared to its average volume of 596,299. Regeneron Pharmaceuticals, Inc. has a 1 year low of $492.13 and a 1 year high of $747.42. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.76 and a quick ratio of 4.09. The stock has a market capitalization of $70.06 billion, a P/E ratio of 9.14, a price-to-earnings-growth ratio of 1.17 and a beta of 0.25. The company’s fifty day simple moving average is $678.51 and its 200-day simple moving average is $645.02.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.37 by $2.12. Regeneron Pharmaceuticals had a net margin of 48.06% and a return on equity of 50.10%. The company had revenue of $2.97 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period last year, the firm posted $10.09 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 17.2% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 40.26 EPS for the current year.
Regeneron Pharmaceuticals Profile (Get Rating)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.